Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-08-147: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) (NCI)

    • Release Date: April 15, 2008
    • Expiration Date: April 12, 2011
    • Contacts:

      Barbara Galen, M.S.N., C.R.N.P., C.N.M.T., NCI, Phone: 301-594-5225, Email: bgalen@mail.nih.gov
      Lalitha Shankar, M.D., NCI, Phone: 301-496-9531, Email: shankarl@mail.nih.gov
      Keyvan Farahani, Ph.D., NCI, Phone: 301-451-2651, Email: farahank@mail.nih.gov

    The goal of this Funding Opportunity Announcement (FOA) is to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) studies, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or Cooperative Groups.

    Mechanism of support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism

    See full description in NIH Guide:PAR-08-147

    For instructions on the inclusion of clinical protocols in the PAR-08-147 application, see NOT-CA-10-019

  • PAR-08-025: Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants (R21)

    • Release Date: November 19, 2007
    • Expiration Date: November 10, 2010
    • Contacts:

      Heng Xie, Ph.D.,, NCI, Phone: 301-496-8866, Email: xiehe@mail.nih.gov

    This Funding Opportunity Announcement (FOA) is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application.

    Mechanism of Support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism

    See full description in NIH Guide:PAR-08-025

  • RFA-CA-08-002: Network for Translational Research (NTR): Optical Imaging in Multimodal Platforms (U54)

    This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is an open competition initiative, designed to continue the efforts of the NCI to develop and translate cancer-relevant optical imaging technologies as a part of an overall imaging program for early cancer detection, diagnosis, therapeutic response, drug development, and image-guided therapy. This FOA stems from the previous initiative on optical imaging technology. However, the program structure and goals of the current FOA differ from those of the original program. Accordingly, all responses to this FOA will be considered new applications, with the main objective being to accelerate the translational research of in vivo multimodal imaging and/or spectroscopic platforms from the laboratory and pre-clinical level to the clinical level. Applications are sought from multi-disciplinary, multi-institutional research teams. After the awards, successful teams will become Centers that will be organized into an interactive network. The network will be called the "Network for Translational Research: Optical Imaging" (NTR). The purpose of NTR is to develop, optimize, and validate imaging technology platforms and methods so that they can enter single or multi-site clinical trials and eventually be incorporated into clinical practice. Applicants responding to this FOA must identify a specific cancer-relevant clinical goal and propose to develop and validate at least one multimodal imaging platform, as defined in this FOA, to address this clinical goal.

    • Letters of Intent Receipt Date: December 24, 2007
    • Set-aside funds: $4.8M per year, $24M over 5 years; approximately 4 awards

    See full description in NIH Guide: RFA-CA-08-002

  • PA-07-356: Clinical Cancer Therapy and Prevention Research (R01)

    The National Cancer Institute (NCI) is seeking research project (R01) applications to conduct translational, clinical, therapeutic, and preventive studies and trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer genetics, cancer epigenetics, and cancer biology, coupled with the development of new anti-cancer agents, into innovative cancer intervention studies and trials. The overall aims of this funding opportunity announcement (FOA) are two-fold: (1) to stimulate the development of innovative cancer prevention and therapy clinical trials with or without laboratory correlative studies; and (2) to support innovative correlative laboratory studies retrospectively and prospectively linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

    • No set-aside

    See full description in NIH Guide: PA-07-356

  • PA-07-041 and PA-07-042: Image-Guided Cancer Interventions (STTR [R41/R42] & SBIR [R43/R44])

    • Release Date: February 20, 2007
    • Application Receipt Date: Multiple dates, see announcements.
    • Contacts:

      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov), Phone: 301-496-9531
      Laurence P. Clarke, Ph.D. (lclarke@mail.nih.gov), Phone: 301-435-9190

    These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

    See full description in NIH Guide: STTR (R41/R42) PA-07-041; SBIR (R43/44) PA-07-042

  • Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01) (PAR-10-169)

    • Release Date: February 12, 2007
    • Application Receipt Date: Multiple dates, see announcement.
    • Expiration Date: May 8, 2013
    • Contacts:

      Houston Baker, Ph.D., Tel 240-276-5908, e-mail bakerhou@mail.nih.gov
      James Deye, Ph.D., Tel 240-276-5705, e-mail deyej@mail.nih.gov

    This Funding Opportunity Announcement (FOA) issued by the Cancer Imaging and Radiation Research Programs of the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either animal or human in vivo imaging, image guided, and/or spectroscopic systems and methods designed to solve targeted cancer problems for cancer research, clinical trials, and/or clinical practice. The partners on each application will establish an inter-disciplinary, multi-institutional research team to work in a strategic alliance to implement a coherent strategy to develop and translate the proposed system or methods with potential for significant impact on preclinical, single, or multisite clinical studies. Partnerships must include at least one lead academic and one lead industrial organization large or small among their numbers. For either preclinical or clinical research, funding may be requested for limited additional copies of prototype systems and methods in order to optimize and validate them across different platforms and/or research sites. Each partnership is encouraged to plan to solve its choice of targeted cancer problem within the five year funding period. This FOA supports clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. It will not support commercial production.

    Note that this revised PAR has provided: (a) a revised definition of translational research consistent with the NCI Translational Research Working Group (TRWG) recommendations, (b) a definition of innovation within the context of the TRWG recommendation, (c) examples of translational research for current commercial and next generation of imaging platforms and (d) modified review criteria within the context of the TRWG recommendations. The intent of the revised PAR is to encourage applications with a strong translational research focus. Note that investigators interested in the creation of research resources to assist in validation of imaging technologies are encouraged to explore collaboration with research networks (U01, U54) consistent with the PAR goals.

    See NIH Guide Announcement http://grants.nih.gov/grants/guide/pa-files/PAR-10-169.html

  • RFA-CA-07-505: The American College of Radiology Imaging Network (ACRIN) (Limited Competition U01)

    • Release Date: February 09, 2007
    • Application Receipt Date: April 10, 2007
    • Contacts:

      Barbara A. Galen, MSN, CRNP, CNMT, Tel: 301-594-5225, e-mail: bgalen@mail.nih.gov

    The Cancer Imaging Program, Division of Cancer Diagnosis and Treatment, the National Cancer Institute (NCI), invites applications for a limited competition Request for Applications (RFA) for the continued support of a unique, multi-center imaging network -- the American College of Radiology Imaging Network (ACRIN; hereafter referred to as the "Network"). The overall objective of this limited competition RFA is to improve the use of imaging in cancer research and cancer care management through further support for the activities of the Network. The Network should continue to focus on investigator-initiated research involving key aspects of imaging technology assessment in oncology. Eligible organizations include the current recipients of the ACRIN awards, which are the American College of Radiology-Philadelphia Headquarters and the Brown University-Biostatistics and Data Management Center. The eligible applicants are expected to submit two linked applications (Network Headquarters application and Biostatistics and Data Management Center application). Both applications will be reviewed together and will receive a single score.

    URL:http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-505.html

  • PAR-06-406: In Vivo Cellular and Molecular Imaging Centers (ICMICs)[P50]

    • Release Date: May 09, 2006
    • Application Receipt Date: August 16, 2006; August 16, 2007
    • Expiration Date: August 17, 2007
    • Contacts:

      Anne E. Menkens, NCI, Phone: 301-496-9531, Email: menkensa@mail.nih.gov

    This is a reissue of PAR-04-069, which was previously released February 27, 2004.

    The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the progress in molecular imaging as the basis for the extraordinary, non-invasive and quantitative analytical tools useful in the diagnosis and treatment of cancer as well as in the laboratory environment to interrogate biological pathways relevant to cancer. The Cancer Imaging Program of the NCI solicits new or competing applications for P50 Research Center Grants for In Vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research with clinical relevance. ICMIC funding is designed to: (1) support unique core facilities; (2) enable the awardees to initiate pilot research in new promising directions; and (3) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.

    See full description in NIH Guide:PAR-06-406

  • PA-06-398: Novel Technologies For In Vivo Imaging (R21/R133)

    This Program Announcement (PA) replaces PA-04-095.

    Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits Phased Innovation (R21/R33) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

    See full description in NIH Guide:PA-06-398

    What is the R21 grant mechanism?
    What is the R33 grant mechanism?

  • PA-06-399: Novel Technologies For In Vivo Imaging (R33)

    This Program Announcement (PA) replaces PA-04-095.

    Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R33 (Phase II, Developmental) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and/or treatment of various diseases.

    See full description in NIH Guide:PA-06-399

    What is the R33 grant mechanism?